LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Accueil・Liste d'Actions・Xencor Inc

Xencor Inc

Fermé

SecteurSoins de santé

11.34 8.72

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

10.36

Max

11.37

Chiffres clés
By Trading Economics
Revenu	-214M -129M
Ventes	-24M 4.5M
BPA	-1.71
Marge bénéficiaire	-2,854.65
Employés	260
EBITDA	-81M -75M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+149.76% upside

Dividendes
By Dow Jones
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-170M 820M
Ouverture précédente	2.62
Clôture précédente	11.34

Sentiment de l'Actualité

By Acuity

34%

66%

89 / 345 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

7.87 / 10.84 Support & Résistance

Xencor Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

20 mai 2026, 23:31 UTC

Actions en Tendance

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 mai 2026, 22:52 UTC

Principaux Mouvements du Marché

Osisko Shares Fall on Planned Convertible Notes Offering

20 mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 mai 2026, 23:44 UTC

Résultats

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 mai 2026, 23:35 UTC

Market Talk

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 mai 2026, 23:30 UTC

Market Talk

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 mai 2026, 23:17 UTC

Market Talk

Global Equities Roundup: Market Talk

20 mai 2026, 23:17 UTC

Market Talk

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 mai 2026, 23:15 UTC

Market Talk

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 mai 2026, 23:14 UTC

Résultats

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 mai 2026, 23:02 UTC

Market Talk

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 mai 2026, 22:57 UTC

Market Talk

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 mai 2026, 22:57 UTC

Market Talk

Global Energy Roundup: Market Talk

20 mai 2026, 22:57 UTC

Market Talk

Global Equities Roundup: Market Talk

20 mai 2026, 22:51 UTC

Market Talk

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 mai 2026, 22:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 mai 2026, 22:27 UTC

Market Talk

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 mai 2026, 22:14 UTC

Market Talk

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 mai 2026, 22:10 UTC

Résultats

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 mai 2026, 22:00 UTC

Résultats

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 mai 2026, 21:38 UTC

Résultats

Acquisitions, Fusions, Rachats

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 mai 2026, 21:27 UTC

Résultats

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 mai 2026, 21:20 UTC

Résultats

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 mai 2026, 21:19 UTC

Résultats

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 mai 2026, 21:18 UTC

Résultats

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 mai 2026, 21:17 UTC

Résultats

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 mai 2026, 21:17 UTC

Résultats

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 mai 2026, 21:17 UTC

Résultats

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 mai 2026, 21:16 UTC

Résultats

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Comparaison

Variation de prix

Xencor Inc prévision

Objectif de Prix

By TipRanks

149.76% hausse

Prévisions sur 12 Mois

Moyen 26 USD 149.76%

Haut 43 USD

Bas 13 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

12 ratings

Achat

Maintien

Vente

Basé sur 12 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

7.87 / 10.84Support & Résistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

89 / 345Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.